FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317257877> ?p ?o ?g. }

• W2317257877 endingPage "160" @default.
• W2317257877 startingPage "154" @default.
• W2317257877 abstract "In Brief Purpose: The purpose of this study was to investigate the effect of intravitreal bevacizumab on an experimental rabbit model of penetrating posterior ocular injury. Methods: The right eyes of 40 white New Zealand rabbits were included in a penetrating posterior ocular injury model that was consisted of a 5-mm circumferential incision placed 8 mm behind the limbus at the supratemporal quadrant. They were randomly divided into two groups. The rabbits in Group 1 (n = 20) received 1.25 mg (0.05 mL) of intravitreal bevacizumab via pars plana injection and those in Group 2 (control group, n = 20) received 0.05 mL of intravitreal balanced salt solution. On Day 28, the eyes were enucleated and evaluated by gross inspection and light microscopy. Clearance time of vitreous hemorrhage, presence of fibrous proliferation or retinal detachment, greatest linear dimension of fibrosis, and grade of fibrous extension were regarded as outcome measures. Nominal variables were evaluated by the chi-square or the Fisher's exact test; continuous variables were evaluated using the Mann-Whitney U test. Results: At the end of the surgery, all the eyes had moderate (n = 9 and 7 in the case and control groups, respectively) or severe vitreous hemorrhage (n = 11 and 13 in the case and control groups, respectively) (P = 0.52). Average clearance time of vitreous hemorrhage was 3.42 ± 2.71 and 6.47 ± 3.58 days in bevacizumab and control groups, respectively (P = 0.01). The incidence of ophthalmoscopically visible fibrous proliferation was 31.6% in the bevacizumab group and 63.2% in the control group (P = 0.05). The greatest linear dimension of fibrosis was 0.91 ± 1.14 mm in the bevacizumab group and 2.00 ± 1.58 mm in the control group (P = 0.02). Retinal detachment rate was 11% (n = 2, all rhegmatogenous) and 21% (n = 4, 2 rhegmatogenous and 2 tractional) in the bevacizumab and control groups, respectively (P = 0.66). Choroidal congestion, optic disk edema, and macular edema were seen in 1 eye (5.5%) of the bevacizumab group, whereas they were found in 4 (22%), 4 (22%) and 3 (16.5%) eyes of the control group, respectively. These differences, however, did not reach statistical significance. Conclusion: This study showed that intravitreal injection of bevacizumab may reduce the extent of fibrovascular and/or fibrocellular proliferation and may accentuate the clearance of vitreous hemorrhage after an experimental model of posterior penetrating ocular injury in rabbits. These alterations may affect the long-term anatomical and/or functional success rate of posterior segment surgeries in these eyes. This study showed that intravitreal injection of bevacizumab may reduce the extent of fibrovascular and/or fibrocellular proliferation and may accentuate the clearance of vitreous hemorrhage after an experimental model of posterior penetrating ocular injury in rabbits. These alterations may affect the long-term anatomical and/or functional success rate of posterior segment surgeries in these eyes." @default.
• W2317257877 created "2016-06-24" @default.
• W2317257877 creator A5016624178 @default.
• W2317257877 creator A5031582978 @default.
• W2317257877 creator A5037767514 @default.
• W2317257877 creator A5076628489 @default.
• W2317257877 creator A5084721434 @default.
• W2317257877 date "2011-01-01" @default.
• W2317257877 modified "2023-09-25" @default.
• W2317257877 title "THE ROLE OF INTRAVITREAL BEVACIZUMAB IN EXPERIMENTAL POSTERIOR PENETRATING EYE INJURY" @default.
• W2317257877 cites W1499105006 @default.
• W2317257877 cites W1760127410 @default.
• W2317257877 cites W1964909463 @default.
• W2317257877 cites W1967172766 @default.
• W2317257877 cites W1967248780 @default.
• W2317257877 cites W1971515439 @default.
• W2317257877 cites W1975216289 @default.
• W2317257877 cites W1976903522 @default.
• W2317257877 cites W1982095171 @default.
• W2317257877 cites W1988478379 @default.
• W2317257877 cites W1998819970 @default.
• W2317257877 cites W2011211800 @default.
• W2317257877 cites W2016926751 @default.
• W2317257877 cites W2030168485 @default.
• W2317257877 cites W2033245558 @default.
• W2317257877 cites W2035319916 @default.
• W2317257877 cites W2047083844 @default.
• W2317257877 cites W2075086348 @default.
• W2317257877 cites W2080913415 @default.
• W2317257877 cites W2081633887 @default.
• W2317257877 cites W2084971593 @default.
• W2317257877 cites W2092306988 @default.
• W2317257877 cites W2096735172 @default.
• W2317257877 cites W2109606826 @default.
• W2317257877 cites W2142451698 @default.
• W2317257877 cites W2143553858 @default.
• W2317257877 cites W2149241796 @default.
• W2317257877 cites W2154459059 @default.
• W2317257877 cites W2157769714 @default.
• W2317257877 cites W2233259956 @default.
• W2317257877 cites W4297917733 @default.
• W2317257877 cites W68981680 @default.
• W2317257877 doi "https://doi.org/10.1097/iae.0b013e3181e096f3" @default.
• W2317257877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20838359" @default.
• W2317257877 hasPublicationYear "2011" @default.
• W2317257877 type Work @default.
• W2317257877 sameAs 2317257877 @default.
• W2317257877 citedByCount "4" @default.
• W2317257877 countsByYear W23172578772014 @default.
• W2317257877 countsByYear W23172578772018 @default.
• W2317257877 countsByYear W23172578772021 @default.
• W2317257877 countsByYear W23172578772023 @default.
• W2317257877 crossrefType "journal-article" @default.
• W2317257877 hasAuthorship W2317257877A5016624178 @default.
• W2317257877 hasAuthorship W2317257877A5031582978 @default.
• W2317257877 hasAuthorship W2317257877A5037767514 @default.
• W2317257877 hasAuthorship W2317257877A5076628489 @default.
• W2317257877 hasAuthorship W2317257877A5084721434 @default.
• W2317257877 hasConcept C113520495 @default.
• W2317257877 hasConcept C118487528 @default.
• W2317257877 hasConcept C141071460 @default.
• W2317257877 hasConcept C191093355 @default.
• W2317257877 hasConcept C2776694085 @default.
• W2317257877 hasConcept C2777063560 @default.
• W2317257877 hasConcept C2777104736 @default.
• W2317257877 hasConcept C2777802072 @default.
• W2317257877 hasConcept C2778257484 @default.
• W2317257877 hasConcept C2780428090 @default.
• W2317257877 hasConcept C2780639617 @default.
• W2317257877 hasConcept C2780827179 @default.
• W2317257877 hasConcept C2781242345 @default.
• W2317257877 hasConcept C71924100 @default.
• W2317257877 hasConceptScore W2317257877C113520495 @default.
• W2317257877 hasConceptScore W2317257877C118487528 @default.
• W2317257877 hasConceptScore W2317257877C141071460 @default.
• W2317257877 hasConceptScore W2317257877C191093355 @default.
• W2317257877 hasConceptScore W2317257877C2776694085 @default.
• W2317257877 hasConceptScore W2317257877C2777063560 @default.
• W2317257877 hasConceptScore W2317257877C2777104736 @default.
• W2317257877 hasConceptScore W2317257877C2777802072 @default.
• W2317257877 hasConceptScore W2317257877C2778257484 @default.
• W2317257877 hasConceptScore W2317257877C2780428090 @default.
• W2317257877 hasConceptScore W2317257877C2780639617 @default.
• W2317257877 hasConceptScore W2317257877C2780827179 @default.
• W2317257877 hasConceptScore W2317257877C2781242345 @default.
• W2317257877 hasConceptScore W2317257877C71924100 @default.
• W2317257877 hasIssue "1" @default.
• W2317257877 hasLocation W23172578771 @default.
• W2317257877 hasLocation W23172578772 @default.
• W2317257877 hasOpenAccess W2317257877 @default.
• W2317257877 hasPrimaryLocation W23172578771 @default.
• W2317257877 hasRelatedWork W1978523567 @default.
• W2317257877 hasRelatedWork W2005639104 @default.
• W2317257877 hasRelatedWork W2021597812 @default.
• W2317257877 hasRelatedWork W2338185683 @default.
• W2317257877 hasRelatedWork W2388371345 @default.
• W2317257877 hasRelatedWork W2415821511 @default.
• W2317257877 hasRelatedWork W2969459224 @default.

• next